Almuradova, E. Et Al. 2024. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. International Journal of Cancer , vol.154, no.4 , 692-700.

Almuradova, E., Seyyar, M., Arak, H., Tamer, F., Kefeli, U., Koca, S., ... Sen, E.(2024). The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. International Journal of Cancer , vol.154, no.4, 692-700.

Almuradova, Elvina Et Al. "The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study," International Journal of Cancer , vol.154, no.4, 692-700, 2024

Almuradova, Elvina Et Al. "The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study." International Journal of Cancer , vol.154, no.4, pp.692-700, 2024

Almuradova, E. Et Al. (2024) . "The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study." International Journal of Cancer , vol.154, no.4, pp.692-700.

@article{article, author={Elvina Almuradova Et Al. }, title={The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study}, journal={International Journal of Cancer}, year=2024, pages={692-700} }